Spots Global Cancer Trial Database for adjuvant treatment
Every month we try and update this database with for adjuvant treatment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Aspirin Treatment for Colon Cancer Patients | NCT02467582 | Colon Cancer | Aspirin Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | NCT02260505 | Gastrointestina... Resected Gastro... Non-metastatic High Risk of Re... KIT Gene Mutati... | Imatinib mainte... | 18 Years - | Centre Leon Berard | |
| Breast Cancer Registry Platform | NCT03417115 | Breast Cancer | 18 Years - | iOMEDICO AG | ||
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | NCT05207735 | Cholangiocarcin... | Sintilimab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | NCT02595138 | Triple Negative... | Zoledronic acid | 18 Years - | ChineseAMS | |
| NADIM II: Neo-Adjuvant Immunotherapy | NCT03838159 | Non Small Cell ... | Paclitaxel Carboplatin Nivolumab | 18 Years - | Fundación GECP | |
| Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | NCT03612219 | Nasopharyngeal ... | Apatinib mesyla... Intensity-modul... Cisplatin | 18 Years - 70 Years | Guilin Medical University, China | |
| Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | NCT04009265 | Esophageal Squa... | adjuvant treatm... | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation | NCT02795884 | NSCLC | intercalation t... Vinorelbine, ci... | 19 Years - | Yonsei University | |
| QOL After SURGERY and ADJUVANT Treatment | NCT06115239 | Carcinoma, Non-... Quality of Life | Questionnaires | 50 Years - 85 Years | University of Salamanca | |
| Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio) | NCT02059668 | Head and Neck C... | Biomarker analy... | 18 Years - | Technische Universität Dresden | |
| Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma | NCT03633552 | Glioblastoma Mu... Anaplastic Astr... | Temozolomide | 18 Years - 70 Years | Mashhad University of Medical Sciences | |
| Docetaxel in Node Positive Adjuvant Breast Cancer | NCT00688740 | Breast Cancer | Docetaxel 5-fluorouracil Doxorubicin Cyclophosphamid... | 18 Years - 70 Years | Sanofi | |
| Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | NCT05114720 | Breast Cancer | standard adjuva... standard adjuva... | 18 Years - 70 Years | Sun Yat-sen University | |
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) | NCT05778097 | Prostate Cancer Biochemical Rec... High Risk | Apalutamide 60m... Androgen depriv... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse | NCT00462865 | Breast Cancer | Gemcitabine and... | 18 Years - 80 Years | Brown University | |
| Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities | NCT00145197 | Breast Cancer | Improving the D... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Tumor Registry Pancreatic Cancer | NCT02089269 | Pancreas Cancer | 18 Years - | iOMEDICO AG | ||
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | NCT04564157 | Non-Small Cell ... Adjuvant Chemot... | Carboplatin Paclitaxel Nivolumab | 18 Years - | Fundación GECP | |
| Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation | NCT01405079 | Non-small Cell ... | Gefitinib Vinorelbine+Cis... | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | NCT04564157 | Non-Small Cell ... Adjuvant Chemot... | Carboplatin Paclitaxel Nivolumab | 18 Years - | Fundación GECP | |
| Tumor Registry Pancreatic Cancer | NCT02089269 | Pancreas Cancer | 18 Years - | iOMEDICO AG | ||
| Safety, Feasibility and Metabolic Effects of the Fasting Mimicking Diet (FMD) in Cancer Patients | NCT03340935 | Malignant Neopl... Cancer | Fasting mimicki... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | NCT04268121 | Neuroendocrine ... Digestive Cance... | Neoadjuvant tre... Adjuvant treatm... | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer | NCT02347904 | Esophageal Canc... | S-1 and Oxalipl... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | NCT04512430 | Non Small Cell ... EGFR Gene Mutat... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | Fundación GECP | |
| Docetaxel in Node Positive Adjuvant Breast Cancer | NCT00688740 | Breast Cancer | Docetaxel 5-fluorouracil Doxorubicin Cyclophosphamid... | 18 Years - 70 Years | Sanofi | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Sorafenib in Resected Non-small Cell Lung Carcinoma | NCT00532025 | Carcinoma, Non-... | Sorafenib | 18 Years - | Johannes Gutenberg University Mainz | |
| A Study of Adjuvant Melanoma Stakeholder Treatment Preferences | NCT05115006 | Melanoma | 18 Years - | Bristol-Myers Squibb | ||
| Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer | NCT00301457 | Breast Cancer | Anastrozole | 45 Years - 99 Years | Maastricht University Medical Center | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer | NCT02347904 | Esophageal Canc... | S-1 and Oxalipl... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | NCT04296162 | Breast Cancer | Vinorelbine Capecitabine Trastuzumab | 18 Years - 70 Years | Fudan University | |
| Docetaxel in Node Positive Adjuvant Breast Cancer | NCT00688740 | Breast Cancer | Docetaxel 5-fluorouracil Doxorubicin Cyclophosphamid... | 18 Years - 70 Years | Sanofi | |
| Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | NCT05114720 | Breast Cancer | standard adjuva... standard adjuva... | 18 Years - 70 Years | Sun Yat-sen University | |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | NCT05207735 | Cholangiocarcin... | Sintilimab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | NCT04790305 | Carcinoma Breas... Triple-negative... Invasive Ductal... | Huaier Granule | 18 Years - 70 Years | Fudan University | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | NCT02595138 | Triple Negative... | Zoledronic acid | 18 Years - | ChineseAMS | |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | NCT00282087 | Leiomyosarcoma Uterine Neoplas... | gemcitabine, do... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | NCT05891093 | Breast Cancer | Fluzoparib Anastrozole Letrozole Exemestane Tamoxifen Toremifene Abemaciclib LHRH agonist | 18 Years - 70 Years | Fudan University | |
| Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | NCT05975749 | Gastric Cancer | Serplulimab Trastuzuma Chemotherapy | 20 Years - 80 Years | Fudan University | |
| Patient Centered Randomized Controlled Trial | NCT00233077 | Early-Stage Bre... | Patient Assista... Information onl... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | NCT06402708 | Thymic Carcinom... | Chemotherapy Radiotherapy | 18 Years - 75 Years | Fudan University | |
| Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | NCT04259944 | Colon Cancer | CAPOX Capecitabine FOLFIRI | 18 Years - | IFOM ETS - The AIRC Institute of Molecular Oncology | |
| Personalized DC Vaccine for Postoperative Cancer | NCT04147078 | Gastric Cancer Hepatocellular ... Non-Small-Cell ... Colon Rectal Ca... | DC vaccine subc... | 18 Years - 100 Years | Sichuan University | |
| Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer | NCT02347904 | Esophageal Canc... | S-1 and Oxalipl... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03427827 | Nasopharyngeal ... | Camrelizumab | 18 Years - 65 Years | Sun Yat-sen University | |
| Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective | NCT05100277 | Breast Cancer Adjuvant Treatm... | Oncotype DX® As... Cost | 18 Years - | Hospital Perola Byington | |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma | NCT03439709 | Acromegaly Due ... | Gamma knife rad... Lanreotide 60Mg... | 18 Years - 70 Years | Samsung Medical Center | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | NCT02595138 | Triple Negative... | Zoledronic acid | 18 Years - | ChineseAMS | |
| Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | NCT04296162 | Breast Cancer | Vinorelbine Capecitabine Trastuzumab | 18 Years - 70 Years | Fudan University | |
| Hyperthermia European Adjuvant Trial | NCT01077427 | Resected Pancre... | Gemcitabine + C... Gemcitabine + C... | 18 Years - 75 Years | Klinikum der Universitaet Muenchen, Grosshadern | |
| Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | NCT04790305 | Carcinoma Breas... Triple-negative... Invasive Ductal... | Huaier Granule | 18 Years - 70 Years | Fudan University | |
| NADIM II: Neo-Adjuvant Immunotherapy | NCT03838159 | Non Small Cell ... | Paclitaxel Carboplatin Nivolumab | 18 Years - | Fundación GECP | |
| Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | NCT05975749 | Gastric Cancer | Serplulimab Trastuzuma Chemotherapy | 20 Years - 80 Years | Fudan University | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | NCT03844750 | Metastatic Mali... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... | Hepatectomy Pembrolizumab Vactosertib | 18 Years - | University of California, San Francisco | |
| A Study of Adjuvant Melanoma Stakeholder Treatment Preferences | NCT05115006 | Melanoma | 18 Years - | Bristol-Myers Squibb | ||
| Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma | NCT01348256 | Colorectal Carc... Hepatic Metasta... | Dendritic cells... | 18 Years - | Clinica Universidad de Navarra, Universidad de Navarra | |
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) | NCT05778097 | Prostate Cancer Biochemical Rec... High Risk | Apalutamide 60m... Androgen depriv... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation | NCT02795884 | NSCLC | intercalation t... Vinorelbine, ci... | 19 Years - | Yonsei University | |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | NCT05207735 | Cholangiocarcin... | Sintilimab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Partial Breast Radiation to the Lumpectomy Cavity With IMRT in Elderly Women | NCT00337064 | Stage I Breast ... | Radiation Thera... | 65 Years - | University of Vermont |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
